Metabolically Controlled Oncological Treatment: An Evidence-Graded Framework Integrating Metabolic Reprogramming, Targeted Drug Delivery, and Standard Oncological Care
4 affiliations
- 1Neolife Oncology Centre, 34340 Istanbul, Türkiye
- 2Department of Infectious Diseases and Clinical Microbiology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye
- 3Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye
- 4Department of Biology, Boston College, Boston, MA 02467, USA
Abstract
Cancer cells exhibit metabolic reprogramming, including increased aerobic glycolysis, glutaminolysis, and altered lipid metabolism, which supports tumor growth and contributes to immune evasion. A growing but heterogeneous body of literature has investigated whether targeting these metabolic dependencies alongside standard oncologic treatment may provide therapeutic benefit. This review critically examines clinically investigated metabolically directed approaches, including metronomic chemotherapy, hyperthermia, high-dose intravenous vitamin C, hyperbaric oxygen therapy, fasting-related nutritional strategies, ketogenic diets, and insulin-based approaches, while distinguishing them from established targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors. Emerging immunometabolic and microenvironmental targets are also discussed, including lactate transport, ferroptosis, autophagy and amino acid metabolism, cancer-associated fibroblasts, tumor-associated macrophages, abnormal vasculature, and immunosuppressive cytokine signaling. In addition, drug-delivery strategies are considered by distinguishing the established pharmaceutical role of dimethyl sulfoxide (DMSO) as a solvent or excipient from nanoparticle-, exosome-, and peptide-based targeting platforms. Available evidence is characterized according to clinical maturity, ranging from established phase III-supported therapies and randomized clinical evidence to early-phase, preclinical, or currently unproven approaches. Although several metabolically directed interventions have biological rationale and varying degrees of clinical support, no comprehensive multicomponent metabolic regimen has been validated in controlled clinical trials. Future development should prioritize stepwise, biomarker-informed prospective studies evaluating individual interventions and biologically justified combinations alongside standard-of-care therapy. Metabolically directed strategies should therefore be interpreted according to the evidence supporting each component rather than as a single established therapeutic regimen.
Related
- Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia
- Chemical proteomics suggests sofosbuvir is metabolically attached to proteins through a UMPylation-like pathway.
- Reprogramming pyrrole reactivity enables skeletal editing to azepines and azepinones
- Skeletal Editing through Reprogramming of the Gabriel–Colman Rearrangement Enables Formation of a Ring-Expanded Spirocycle
- Antimycin A Improves Heat Tolerance in Creeping Bentgrass by Suppressing Nighttime Respiration and Reprogramming Carbon and Nitrogen Metabolism.
BibTeX
@article{iyikesici2026metabolically,
title = {{Metabolically Controlled Oncological Treatment: An Evidence-Graded Framework Integrating Metabolic Reprogramming, Targeted Drug Delivery, and Standard Oncological Care}},
author = {Mehmet Salih Iyikesici and Oral Oncul and Sena Sen and Sirin Budak and Thomas N. Seyfried and Tomas Duraj},
journal = {Molecules},
year = {2026},
month = nov,
doi = {10.3390/molecules31213970},
url = {https://www.mdpi.com/1420-3049/31/21/3970},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metabolically Controlled Oncological Treatment: An Evidence-Graded Framework Integrating Metabolic Reprogramming, Targeted Drug Delivery, and Standard Oncological Care
AU - Mehmet Salih Iyikesici
AU - Oral Oncul
AU - Sena Sen
AU - Sirin Budak
AU - Thomas N. Seyfried
AU - Tomas Duraj
PY - 2026
DA - 2026/11/03
JO - Molecules
DO - 10.3390/molecules31213970
UR - https://www.mdpi.com/1420-3049/31/21/3970
AB - Cancer cells exhibit metabolic reprogramming, including increased aerobic glycolysis, glutaminolysis, and altered lipid metabolism, which supports tumor growth and contributes to immune evasion. A growing but heterogeneous body of literature has investigated whether targeting these metabolic dependencies alongside standard oncologic treatment may provide therapeutic benefit. This review critically examines clinically investigated metabolically directed approaches, including metronomic chemotherapy, hyperthermia, high-dose intravenous vitamin C, hyperbaric oxygen therapy, fasting-related nutritional strategies, ketogenic diets, and insulin-based approaches, while distinguishing them from established targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors. Emerging immunometabolic and microenvironmental targets are also discussed, including lactate transport, ferroptosis, autophagy and amino acid metabolism, cancer-associated fibroblasts, tumor-associated macrophages, abnormal vasculature, and immunosuppressive cytokine signaling. In addition, drug-delivery strategies are considered by distinguishing the established pharmaceutical role of dimethyl sulfoxide (DMSO) as a solvent or excipient from nanoparticle-, exosome-, and peptide-based targeting platforms. Available evidence is characterized according to clinical maturity, ranging from established phase III-supported therapies and randomized clinical evidence to early-phase, preclinical, or currently unproven approaches. Although several metabolically directed interventions have biological rationale and varying degrees of clinical support, no comprehensive multicomponent metabolic regimen has been validated in controlled clinical trials. Future development should prioritize stepwise, biomarker-informed prospective studies evaluating individual interventions and biologically justified combinations alongside standard-of-care therapy. Metabolically directed strategies should therefore be interpreted according to the evidence supporting each component rather than as a single established therapeutic regimen.
SN - 1420-3049
ER -